Pharmaceuticals firm, Mylan launches generic Hepatitis C drug in India

Mylan Pharmaceuticals on Thursday launched its generic drug Harvoni under the brandname MyHep LVIRTM in India.

The drug is a combination of Ledipasvir/Sofosbuvir and is indicated for the treatment of Hepatitis C infection. It offers a simplified Hepatitis C treatment regimen that eliminates the need for interferon and ribavirin. 

The drug is also a single-tablet regimen and requires a therapy course of 12 weeks.

"MyHep LVIRTM is an important addition to our growing Hepato Care segment in India that gives us the opportunity to offer patients the potential to be cured through a transformative and simplified single tablet, once-daily treatment regimen," said Mylan Pharma President Rajiv Malik.

The launch of MyHep LIVR follows the launch of generic Sofosbuvir in India under the brand name MyHep in April, 2015.

It may be recalled that in September 2014, Mylan had entered into a licensing and technology transfer agreement with Gilead Sciences for non-exclusive rights to manufacture and distribute these Hepatitis C drugs in developing countries, including India.

In February 2015, Mylan entered into an agreement with Gilead as the exclusive distributor of Gilead's branded Sovaldi (Sofosbuvir 400 mg) and Harvoni tablets in India. 

Mylan launched Sovaldi in India in May 2015. 

There are around 12 million people who are chronically infected with Hepatitis C in India.

To know more about the latest update on this treatment protocol and treating centers offering the same as well as for getting your reports reviewed, post a query